Related Experiment Video

Updated: Aug 14, 2026

Breath Collection from Children for Disease Biomarker Discovery
06:09

Breath Collection from Children for Disease Biomarker Discovery

Published on: February 14, 2019

The BNF for children

    Drug and Therapeutics Bulletin
    |November 22, 2005
    PubMed

    Insights

    Pediatric medicine often differs from adult care, with many treatments used off-label or unlicensed for children. The British National Formulary for Children (BNFC) publication addresses this gap, offering crucial guidance for pediatric healthcare providers.

    Area of Science:

    • Pediatric pharmacology and therapeutics.
    • Evidence-based medicine in child healthcare.

    Background:

    • Medical conditions, treatments, and responses in children frequently differ from adults.
    • A significant proportion of medications prescribed to children are unlicensed or used off-label in general practice.
    • This highlights a critical need for specialized pediatric drug information.

    Purpose of the Study:

    • To review the newly published British National Formulary for Children (BNFC).
    • To assess the BNFC's importance in addressing the challenges of pediatric prescribing.

    Main Methods:

    • Review of the British National Formulary for Children (BNFC) publication.
    • Analysis of the context and implications of unlicensed and off-label medication use in pediatric populations.

    Main Results:

    • The launch of the BNFC in September 2005 is identified as a significant development.
    • The review acknowledges the prevalence of off-label and unlicensed medication use in pediatric care.

    Conclusions:

    • The BNFC is a crucial resource for improving the safe and effective prescribing of medications for children.
    • This publication aims to mitigate risks associated with pediatric medication use by providing authoritative guidance.

    More Related Videos

    Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

    Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

    Published on: August 25, 2014

    Related Concept Videos

    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...